Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunoglobulin (Privigen®) Therapy to Treat BK Viremia and Prevent Alloimmune Activation in Kidney Transplant Recipients

NCT02659891 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT02659891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02659891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunoglobulin (Privigen®) Therapy to Treat BK Viremia and Prevent Alloimmune Activation in Kidney Transplant Recipients
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2016
Completion date
March 31, 2021
Enrollment
16 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bk virus, isoantibodies, kidney transplantation